温馨提示:本文中所涉及的信息旨在传递医药前沿信息和研究进展,不涉及诊疗方案推荐,临床上请遵从医生或其他医疗卫生专业人士的意见与指导。
封面图片:摄图网+稿定设计
责任编辑:觅健科普君
参考来源:
[1] Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023, 27(1):85-102. doi: 10.1016/j.cld.2022.08.004.
[2] Qin S, Ren Z, Feng Y-H, et al. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer, 2021, 10:296-308. 10.1159/000513486.
[3] Finn RS, Ikeda M, Zhu AX, et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol, 2020,38:2960-70. doi:10.1200/JCO.20.00808.
[4] Jian Zhou, et al. ASCO 2023. Poster 4126.
[5] Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020, 7(3):359-369. doi: 10.1016/j.gendis.2020.02.002
[6] Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019, 25(28):3704-3721. doi: 10.3748/wjg.v25.i28.3704.
[7] Yin Z, Chen D, Liang S, et al. Neoadjuvant Therapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2022, 9:929-946. doi: 10.2147/JHC.S357313.
[8] Jian Zhou, et al. ASCO 2023. Poster 4023.
[9] Zhao Y, Ma Y, Zang A, et al. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023, 16(1):50. doi: 10.1186/s13045-023-01445-1.
[10] Jian Zhou, et al. ASCO 2023. Poster 4077.